Recent advances: the cytochrome P450 enzymes

Successful application of information on cytochrome P450 to prevent drug interactions and improve the therapeutic risk: benefit ratio can occur only if we know which enzyme is responsible for the metabolism of a drug. Until recently, this information was not usually available when new drugs reached the market. It is not enough to know the fraction of a dose metabolized versus excreted unchanged or the metabolic pathways by which a compound is degraded. Studies conducted during drug development must identify the enzyme or enzymes involved in the metabolism of new drugs. In addition, the ability of new drugs to inhibit or induce the activity of the key P450 enzymes must be known if we are to take full advantage of our current knowledge of how the cytochrome P450 system works.

This article has been cited by other articles:

				S. Krishnan and S. Moncrief An Evaluation of the Cytochrome P450 Inhibition Potential of Lisdexamfetamine in Human Liver Microsomes Drug Metab. Dispos., January 1, 2007; 35(1): 180 - 184. [Abstract] [Full Text] [PDF]

				G. Iohom, D. Fitzgerald, and A. J. Cunningham Principles of pharmacogenetics--implications for the anaesthetist Br. J. Anaesth., September 1, 2004; 93(3): 440 - 450. [Full Text] [PDF]

				K. B Rao, M. Pallaki, S. R Tolbert, and T. R Hornick Enhanced Hypoprothrombinemia with Warfarin Due to Azithromycin Ann. Pharmacother., June 1, 2004; 38(6): 982 - 985. [Abstract] [Full Text] [PDF]

				M. B. Dowd Anticoagulation in the Elderly Journal of Pharmacy Practice, April 1, 2004; 17(2): 94 - 102. [Abstract] [PDF]

				M. A. Sarkar, V. Vadlamuri, S. Ghosh, and D. D. Glover Expression and Cyclic Variability of CYP3A4 and CYP3A7 Isoforms in Human Endometrium and Cervix During the Menstrual Cycle Drug Metab. Dispos., January 1, 2003; 31(1): 1 - 6. [Abstract] [Full Text] [PDF]

				M. H. Davidson Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2001; 6(3): 219 - 229. [Abstract] [PDF]

				Why bother about cytochrome P450 enzymes? DTB, December 1, 2000; 38(12): 93 - 96. [Abstract] [Full Text] [PDF]

				H. Gutgesell, D. Atkins, R. Barst, M. Buck, W. Franklin, R. Humes, R. Ringel, R. Shaddy, and K. A. Taubert Cardiovascular Monitoring of Children and Adolescents Receiving Psychotropic Drugs : A Statement for Healthcare Professionals From the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association Circulation, February 23, 1999; 99(7): 979 - 982. [Full Text] [PDF]

				S. S. Surapaneni, M. P. Clay, L. A. Spangle, J. W. Paschal, and T. D. Lindstrom In Vitro Biotransformation and Identification of Human Cytochrome P450 Isozyme-Dependent Metabolism of Tazofelone Drug Metab. Dispos., December 1, 1997; 25(12): 1383 - 1388. [Abstract] [Full Text]